NEW YORK, July 28, 2011 /PRNewswire/ -- Investor Uprising
Confidential, the premium investment research service of Investor
Uprising, has published its "Best of Biotech: Innovation in Life
Sciences" report today. The 16-page report covers the hottest
trends in biotech investing, tells investors how to get involved,
and gives an overview of more than 16 companies including a model
portfolio of 10 top stock picks.
(Logo: http://photos.prnewswire.com/prnh/20110728/NY41230LOGO
)
Biotech stocks have been among the best performers of the last
five years, according to Investor Uprising Confidential's research,
and many of these gains are driven by scientific innovation in the
biopharmaceuticals and diagnostics markets. This innovation cycle
is likely to continue for some time, making biotech an attractive
place to invest.
"Many investors remain unaware of the strength in biotech and
are mystified about how to invest in the market," says Investor
Uprising Confidential's Editor and Publisher, R. Scott Raynovich. "Consequently, they have
missed out. We put together a report that covers all the trends and
explains many different ways to get involved, including ETFs,
mutual funds, and individual stocks."
The report includes summaries of 17 leading biotechnology
companies, three mutual funds, and the leading biotech Exchange
Traded Funds (ETFs). Among the companies included in the report are
Amgen Inc. (Nasdaq: AMGN), Biogen Idec (Nasdaq: BIIB),
Celgene Inc. (Nasdaq: CELG), Gilead Sciences Inc. (Nasdaq: GILD),
Vertex Pharmaceuticals Inc. (Nasdaq: VRTX), BioMarin Pharmaceutical
Inc. (Nasdaq: BMRN), Cubist Pharmaceuticals Inc. (Nasdaq: CBST),
Dendreon Corp. (Nasdaq: DNDN), Illumina Inc. (Nasdaq: ILMN), and
Seattle Genetics Inc. (Nasdaq: SGEN).
Investor Uprising Confidential produces premium in-depth reports
aimed at informing the sophisticated investor about long-term
trends in important growth markets. The Best of Biotech report is
available as a single copy at $500,
or as part of an Investor Uprising Confidential annual
subscription. To look at the executive summary of the Biotech and
the research service, go to
http://www.investoruprising.com/confidential.
Sponsored by PR Newswire, Investor Uprising, as well as the
recent launch of the "My News" feature on PRNewswire.com and
monthly virtual Retail Investor Conferences
(retailinvestorconferences.com), represents PR Newswire's strategy
to facilitate engagement between the individual investor community
and public companies.
About Investor Uprising
Investor Uprising is the individual investor's
no-nonsense community for accessing business trends and investment
strategies. Combining expert market commentary, fundamental
analysis and on-the-ground reporting, Investor Uprising helps the
reader find the best investment opportunities in global markets.
Sponsored by PR Newswire and operated by UBM plc, Investor
Uprising's community of contributors will reach millions of
potential business readers around the world.
Media Contacts:
R. Scott Raynovich
Editor in Chief, Investor Uprising Confidential
(406) 582-5886 direct
(406) 599-7873 mobile
Scott.Raynovich@investoruprising.com
Noreen Seebacher
Community Editor, Investor Uprising
(201) 360-6773
Noreen.Seebacher@investoruprising.com
SOURCE Investor Uprising